Hematology Laboratory-Blood Bank ARETAIEION Hospital, School of Medicine, National and Kapodistrian University of Athens, Vasilissis Sofias 76, 11526, Athens, Greece.
Eur J Clin Pharmacol. 2022 Oct;78(10):1555-1565. doi: 10.1007/s00228-022-03365-4. Epub 2022 Jul 23.
Low molecular weight heparins (LMWHs) are a group of heterogenous moieties, long used in the prevention and treatment of thrombosis. They derive from heparin and since they are prepared by different methods of depolymerization, they differ in pharmacokinetic properties and anticoagulant profiles, and thus are not clinically interchangeable.
In this review we provide an overview of tinzaparin's main characteristics and uses.
Tinzaparin which is produced by the enzymatic depolymerization of unfractionated heparin (UFH) can be used for the treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE); it has been also used in special populations such as elders, obese, pregnant women, and patients with renal impairment and/or cancer with favorable outcomes in both safety and efficacy, with a once daily dose regimen. Furthermore, LMWHs are extensively used in clinical practice for both thromboprophylaxis and thrombosis treatment of COVID-19 patients.
Tinzaparin features support the hypothesis for having a role in immunothrombosis treatment (i.e. in the context of cancer ,COVID-19), interfering not only with coagulation cascade but also exhibiting anti-inflammatory potency.
低分子量肝素（LMWHs）是一组不均一的物质，长期用于预防和治疗血栓形成。它们源自肝素，由于它们是通过不同的解聚方法制备的，因此在药代动力学特性和抗凝谱方面存在差异，因此在临床上不能互换。
在这篇综述中，我们提供了 tinzaparin 的主要特征和用途概述。
tinzaparin 是通过未分级肝素（UFH）的酶解聚产生的，可用于治疗和预防深静脉血栓形成（DVT）和肺栓塞（PE）；它也已在特殊人群中使用，如老年人、肥胖者、孕妇以及肾功能不全和/或癌症患者，在安全性和疗效方面均有良好的结果，每日一次剂量方案。此外，LMWHs 在 COVID-19 患者的血栓预防和治疗中广泛应用于临床实践。
tinzaparin 的特点支持其在免疫血栓形成治疗中的作用假说（即在癌症、COVID-19 等情况下），不仅干扰凝血级联反应，而且还具有抗炎作用。
